CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
14.13
3.52%
Market Trading Hours* (UTC) Opens on Friday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.17
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Zai Lab Ltd ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 13.64
Open* 13.34
1-Year Change* -65.24%
Day's Range* 13.34 - 14.13
52 wk Range 22.35-47.00
Average Volume (10 days) 425.16K
Average Volume (3 months) 9.99M
Market Cap 2.28B
P/E Ratio -100.00K
Shares Outstanding 969.04M
Revenue 263.49M
EPS -3.12
Dividend (Yield %) N/A
Beta 1.17
Next Earnings Date Feb 28, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 17, 2024 13.64 -0.54 -3.81% 14.18 14.18 13.57
Apr 16, 2024 14.27 0.33 2.37% 13.94 14.50 13.94
Apr 15, 2024 14.07 0.09 0.64% 13.98 14.36 13.88
Apr 12, 2024 14.24 -0.40 -2.73% 14.64 14.82 14.15
Apr 11, 2024 14.94 -0.29 -1.90% 15.23 15.27 14.91
Apr 10, 2024 15.33 -0.37 -2.36% 15.70 15.79 15.01
Apr 9, 2024 15.88 0.18 1.15% 15.70 16.06 15.54
Apr 8, 2024 15.37 -0.04 -0.26% 15.41 15.65 15.13
Apr 5, 2024 15.44 0.20 1.31% 15.24 15.79 15.09
Apr 4, 2024 15.35 -0.20 -1.29% 15.55 15.72 15.22
Apr 3, 2024 15.82 0.18 1.15% 15.64 15.95 15.38
Apr 2, 2024 15.96 -0.13 -0.81% 16.09 16.40 15.74
Apr 1, 2024 16.63 0.69 4.33% 15.94 16.66 15.87
Mar 28, 2024 15.92 -0.33 -2.03% 16.25 16.27 15.86
Mar 27, 2024 16.10 -0.03 -0.19% 16.13 16.54 15.47
Mar 26, 2024 15.88 -0.10 -0.63% 15.98 16.20 15.70
Mar 25, 2024 16.15 0.09 0.56% 16.06 16.34 15.84
Mar 22, 2024 16.07 -0.08 -0.50% 16.15 16.71 16.01
Mar 21, 2024 17.13 -0.11 -0.64% 17.24 17.68 16.90
Mar 20, 2024 17.10 -0.61 -3.44% 17.71 17.78 16.82

Zai Lab Limited Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 215.04 144.312 48.958 12.985 0.12945
Total Operating Expense 619.397 844.376 350.759 216.181 141.898
Selling/General/Admin. Expenses, Total 258.971 218.831 111.312 70.211 21.5759
Research & Development 286.408 573.306 222.711 142.221 120.278
Operating Income -404.357 -700.064 -301.801 -203.196 -141.768
Interest Income (Expense), Net Non-Operating -41.821 2.19 4.939 7.939 3.22096
Other, Net 3.113 -5.54 29.076 0.938 0.05878
Net Income Before Taxes -443.065 -703.414 -267.786 -194.319 -138.488
Net Income After Taxes -443.065 -703.414 -267.786 -194.319 -138.488
Net Income Before Extra. Items -443.286 -704.471 -268.905 -195.071 -139.075
Net Income -443.286 -704.471 -268.905 -195.071 -139.075
Income Available to Common Excl. Extra. Items -443.286 -704.471 -268.905 -195.071 -139.075
Income Available to Common Incl. Extra. Items -443.286 -704.471 -268.905 -195.071 -139.075
Dilution Adjustment
Diluted Net Income -443.286 -704.471 -268.905 -195.071 -139.075
Diluted Weighted Average Shares 958.067 929.921 77.6677 64.3695 52.6098
Diluted EPS Excluding Extraordinary Items -0.46269 -0.75756 -3.46225 -3.03049 -2.64352
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -0.46269 -0.75756 -3.46225 -3.03049 -2.64352
Equity In Affiliates -0.221 -1.057 -1.119 -0.752 -0.58655
Revenue 215.04 144.312 48.958 12.985 0.12945
Cost of Revenue, Total 74.018 52.239 16.736 3.749 0.04359
Gross Profit 141.022 92.073 32.222 9.236 0.08586
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 68.864 62.797 62.601 57.54 48.176
Revenue 68.864 62.797 62.601 57.54 48.176
Cost of Revenue, Total 23.763 21.337 20.924 20.044 17.407
Gross Profit 45.101 41.46 41.677 37.496 30.769
Total Operating Expense 158.365 132.319 159.894 186.123 146.892
Selling/General/Admin. Expenses, Total 67.92 62.51 72.024 66.555 63.401
Research & Development 76.682 48.472 66.946 99.524 66.084
Operating Income -89.501 -69.522 -97.293 -128.583 -98.716
Interest Income (Expense), Net Non-Operating -29.989 19.144 -47.056 3.872 1.175
Other, Net -1.405 1.234 82.58 -36.479 -40.392
Net Income Before Taxes -120.895 -49.144 -61.769 -161.19 -137.933
Net Income After Taxes -120.895 -49.144 -61.769 -161.19 -137.933
Equity In Affiliates 0 0 0 0 0
Net Income Before Extra. Items -120.895 -49.144 -61.769 -161.19 -137.933
Net Income -120.895 -49.144 -61.769 -161.19 -137.933
Income Available to Common Excl. Extra. Items -120.895 -49.144 -61.769 -161.19 -137.933
Income Available to Common Incl. Extra. Items -120.895 -49.144 -61.769 -161.19 -137.933
Diluted Net Income -120.895 -49.144 -61.769 -161.19 -137.933
Diluted Weighted Average Shares 964.817 961.445 959.949 959.086 957.685
Diluted EPS Excluding Extraordinary Items -0.1253 -0.05111 -0.06435 -0.16807 -0.14403
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.13567 -0.05111 -0.06435 -0.16807 -0.14403
Unusual Expense (Income) -10
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 1124.34 1500.88 1216.04 292.464 269.144
Cash and Short Term Investments 1008.47 1409.1 1186.79 275.932 263.302
Cash 1007.42 663.472 441.283 75.111 36.778
Cash & Equivalents 1.047 300.628 0.833 0.821 26.1736
Prepaid Expenses 35.674 18.021 10.935 6.736 5.74926
Total Assets 1220.14 1609.96 1297.64 355.153 301.987
Property/Plant/Equipment, Total - Net 77.375 57.291 46.863 36.424 20.4945
Property/Plant/Equipment, Total - Gross 99.439 73.716 57.115 41.885 22.7024
Accumulated Depreciation, Total -22.064 -16.425 -10.252 -5.461 -2.20792
Intangibles, Net 8.403 9.659 9.44 8.803 0.32157
Long Term Investments 6.431 15.605 1.279 2.398 3.14986
Note Receivable - Long Term 0 23.858 22.141 13.737 8.04426
Other Long Term Assets, Total 3.595 2.662 1.879 1.327 0.83259
Total Current Liabilities 139.842 192.901 98.043 46.635 48.8415
Accounts Payable 65.974 126.163 62.641 22.66 37.432
Accrued Expenses 38.739 31.612 18.9 13.941 3.69917
Notes Payable/Short Term Debt 0 0 0 6.45 3.64262
Other Current Liabilities, Total 35.129 35.126 16.502 3.584 4.06767
Total Liabilities 174.545 230 128.293 60.493 50.9054
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 34.703 37.099 30.25 13.858 2.06394
Total Equity 1045.59 1379.96 1169.34 294.66 251.082
Redeemable Preferred Stock
Common Stock 0.006 0.006 0.005 0.004 0.00348
Additional Paid-In Capital 2893.12 2825.95 1897.47 734.734 498.043
Retained Earnings (Accumulated Deficit) -1861.36 -1418.07 -713.603 -444.698 -249.627
Other Equity, Total 25.685 -23.645 -14.524 4.62 2.66173
Total Liabilities & Shareholders’ Equity 1220.14 1609.96 1297.64 355.153 301.987
Total Common Shares Outstanding 960.22 95.4981 87.811 68.2373 49.9126
Short Term Investments 0 445 744.676 200 200.35
Total Receivables, Net 48.571 54.809 5.165 3.791 0.08971
Accounts Receivable - Trade, Net 39.963 47.474 5.165 3.791 0.08971
Total Inventory 31.621 18.951 13.144 6.005 0.00382
Treasury Stock - Common -11.856 -4.279
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 959.731 1017.51 1072.3 1124.34 1209.83
Cash and Short Term Investments 820.406 874.655 930.394 1008.47 1119.48
Cash 787.725 858.089 878.786 1007.42 818.407
Cash & Equivalents 1.081 1.066 1.058 1.047 301.069
Short Term Investments 31.6 15.5 50.55 0 0
Total Receivables, Net 65.275 68.064 60.727 48.571 39.067
Accounts Receivable - Trade, Net 41.596 47.283 43.346 39.963 27.736
Total Inventory 44.229 36.353 38.405 31.621 29.131
Prepaid Expenses 29.821 38.433 42.772 35.674 22.157
Total Assets 1043.69 1106.37 1170.07 1220.14 1298.51
Property/Plant/Equipment, Total - Net 71.68 74.947 78.457 77.375 70.797
Property/Plant/Equipment, Total - Gross 99.27 100.569 102.936 99.439 91.11
Accumulated Depreciation, Total -27.59 -25.622 -24.479 -22.064 -20.313
Intangibles, Net 4.625 4.757 8.399 8.403 8.364
Long Term Investments 4.466 5.128 6.872 6.431 3.316
Note Receivable - Long Term 0 0.006
Other Long Term Assets, Total 3.192 4.036 4.048 3.595 6.2
Total Current Liabilities 124.896 133.354 124.56 139.842 155.548
Accounts Payable 55.02 67.031 66.361 65.974 90.112
Accrued Expenses 32.932 26.275 18.79 38.739 32.188
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 36.944 40.048 39.409 35.129 33.248
Total Liabilities 162.715 174.059 168.832 174.545 192.645
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 37.819 40.705 44.272 34.703 37.097
Total Equity 880.979 932.314 1001.24 1045.59 1105.87
Common Stock 0.006 0.006 0.006 0.006 0.006
Additional Paid-In Capital 2954.36 2932.05 2911.45 2893.12 2877.36
Retained Earnings (Accumulated Deficit) -2100.55 -2031.4 -1910.5 -1861.36 -1799.59
Other Equity, Total 47.952 52.18 17.272 25.685 39.549
Total Liabilities & Shareholders’ Equity 1043.69 1106.37 1170.07 1220.14 1298.51
Total Common Shares Outstanding 969.037 968.566 963.689 960.22 959.725
Treasury Stock - Common -20.79 -20.526 -16.986 -11.856 -11.456
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -443.286 -704.471 -268.905 -195.071 -139.075
Cash From Operating Activities -367.642 -549.231 -216.055 -191.011 -97.538
Cash From Operating Activities 8.227 6.487 4.64 3.766 1.63438
Amortization 0.0154
Non-Cash Items 133.187 124.275 29.935 23.577 12.5049
Changes in Working Capital -65.77 24.478 18.275 -23.283 27.3822
Cash From Investing Activities 420.016 249.957 -554.83 -14.892 -212.554
Capital Expenditures -24.984 -18.948 -10.669 -15.242 -10.1178
Other Investing Cash Flow Items, Total 445 268.905 -544.161 0.35 -202.436
Cash From Financing Activities -1.73 820.202 1132.44 219.302 144.147
Issuance (Retirement) of Stock, Net 5.87 824.455 1138.97 216.401 140.504
Foreign Exchange Effects -6.274 1.116 4.862 0.091 -0.76342
Net Change in Cash 44.37 522.044 366.417 13.49 -166.709
Cash Interest Paid 0 0 0.189 0.288 0.0358
Issuance (Retirement) of Debt, Net 0 0 -6.527 2.901 3.64262
Financing Cash Flow Items -7.6 -4.253
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -49.144 -443.286 -381.517 -220.327 -82.394
Cash From Operating Activities -69.287 -367.642 -258.35 -132.027 -87.127
Cash From Operating Activities 2.657 8.227 6.1 3.874 2.013
Non-Cash Items 9.255 133.187 134.847 41.836 20.867
Cash Interest Paid 0
Changes in Working Capital -32.055 -65.77 -17.78 42.59 -27.613
Cash From Investing Activities -53.954 420.016 424.389 -143.869 -30.144
Capital Expenditures -3.516 -24.984 -20.611 -13.595 -9.895
Other Investing Cash Flow Items, Total -50.438 445 445 -130.274 -20.249
Cash From Financing Activities -3.886 -1.73 -1.531 -2.24 0.258
Issuance (Retirement) of Stock, Net 1.197 5.87 5.64 4.619 0.297
Issuance (Retirement) of Debt, Net 0
Foreign Exchange Effects -1.299 -6.274 -9.132 -5.144 -0.13
Net Change in Cash -128.426 44.37 155.376 -283.28 -117.143
Financing Cash Flow Items -5.083 -7.6 -7.171 -6.859 -0.039

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Zai Lab Limited Company profile

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC. The company's drug candidates also comprise ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; and ZL-2302 to treat non-small cell lung cancer. The company, through its subsidiary, Zai Lab (Shanghai) Co. Ltd., has a collaboration agreement with the NovoCure Limited to perform clinical studies, sell, and import tumor treating field products in the field of oncology. Zai Lab Limited was founded in 2013 and is headquartered in Shanghai, the People's Republic of China.
Industry: Biopharmaceuticals

4560 Jinke Road
Bldg. 1, 4/F
SHANGHAI
SHANGHAI 201210
CN

Income Statement

  • Annual
  • Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

People also watch

Gold

2,380.42 Price
+0.800% 1D Chg, %
Long position overnight fee -0.0190%
Short position overnight fee 0.0108%
Overnight fee time 21:00 (UTC)
Spread 0.31

XRP/USD

0.51 Price
+2.370% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

US100

17,368.20 Price
-0.780% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

BTC/USD

63,534.05 Price
+4.330% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading